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A Message from the President

In 1994, The Rockefeller University celebrated the 50th anniversary
of what the great immunologist Peter Medawar called "the most interesting
and portentous biological experiment of the 20th century": the discovery
that DNA carries genetic information. This revolutionary finding by
Oswald Avery, Colin MacLeod and Maclyn McCarty, the fruit of fifteen
years of painstaking work in Avery's pneumonia-research laboratory at
The Rockefeller Hospital, was first published in The Journal ofExperimental
Medicine on February 1, 1944. As, the late Lewis Thomas wrote: "This

single discovery opened the way into the biological revolution which
continues to transform our view of nature in the most intimate details, and
continues as well to cast up, in its wake, one biotechnology after another for the comprehension
and, it can be hoped, the reversal of human disease processes."
In this issue of Search, we trace both the historical roots of the Avery laboratory's 1944 paper,
and an array of remarkable new discoveries that have flowed from it. "The Legacy of Avery"
shows how Avery's pneumonia research program led to the DNA discovery, and how our new
found ability to read and manipulate DNA is being used by Dr. Vincent Fischetti in the continu
ing fight against infectious disease microbes. "The Bugs Are Back" describes Dr. Alex Tomasz's
research and public health efforts in understanding and designing new therapies against antibiot
ic-resistant bacteria, one of the major medical problems in the world today. "Following the
Thread of Life" profiles the work of five leading young DNA researchers at the universityDrs. Stephen Burley, Frederick Cross, Stephen DiNardo, Jeffrey Friedman and Titia de Lange.
Dr. Friedman's recent and much-heralded discovery of the first gene linked to the regulation of
body weight, providing a new foundation for the study of the molecular basis of human obesity,
is a shining example of how modern DNA science is changing the face of medical research.
"Opening Pandora's Box" discusses some of the ethical issues arising from our newfound knowl
edge in the context of Dr. Nancy Wexler's quest for the Huntington's disease gene. Highlights
from our year-long celebration of Avery, MacLeod and McCarty's revolutionary finding are
pictured in a special photo essay.
A particularly exciting highlight occurred on September 30, when Professor Emeritus
Maclyn McCarty received the Albert Lasker Special Public Health Award-only the fifth time
in the distinguished history of the Lasker Awards that this special recognition has been given.
Like Avery, Mac is a famously modest man, who would readily echo a favorite saying of his
mentor's: "Apply the brakes when tempted to blow your own horn." One of the great pleasures
of this anniversary year has been the opportunity for the university community and scientific
world to blow the trumpet for Mac, and for the late Oswald Avery and Colin MacLeod.

Torsten Wiesel
President

From

Infe-ctious
It was called the "crisis."

Above, Members of the Avery laboratory, about 1932. (From left to righn,
Seated: Thomas Francis, Jr., Oswald Avery, Walther F. Goebel. Standing:
Edward E. Terrell, Kenneth Goodner, Rene J. Dubas, Frank H. Babers.

Ten or twelve days after the first signs of sickness,
the pneumonia patient's fever would rise precipitous
ly; the bacterial infection of the lungs would peak;
the patient's immune system would either launch
a successful attack against the invading bacteria,
or the patient would die. One-fifth of pneumonia
victims did not survive the crisis; four-fifths recovered.
At the turn of the 20th century, when The Rockefeller
Institute for Medical Research was established, lobar
pneumonia was the nation's leading cause of fatality.
The great English physician William Osler called
pneumonia "Captain of the Men of Death."
Pneumonia was, Osler said, "a self-limited disease
which can neither be aborted nor cut short
by any means at our command."
For Oswald T. Avery, the key to the pneumonia
crisis was contained in small vials of sugar. Between
1913, when he was recruited to work on pneumonia
therapy at The Rockefeller Hospital, and the late
1920s, Avery and several brilliant collaborators
discovered that these complex sugars, or polysaccha
rides, composed the protective capsules surrounding
pneumococci bacteria, shielding them and preventing
their engulfment by bacteria-eating immune cells
called phagocytes.
Different types of pneumococci were protected
by capsules made of different polysaccharides.
Avery's initial research at Rockefeller was aimed at
isolating animal antibodies against the capsules of
different pneumococcal types, which could then be
injected into human pneumonia patients before they
reached the crisis. Until the advent of antibiotics, this
"serum therapy" was medicine's only weapon against
lobar pneumonia.
This work helped usher in the era of antibiotics,

The Legacy of Avery:

Disease to DNA

by Geoffrey Montgomery

and in the process established the paradigm for the
modern study, diagnosis and treatment of all infec
tious diseases. And it was a mysterious phenomenon
involving this sugary capsule that also led Avery,
Colin Macleod and Maclyn McCarty to what the
Nobel Prize-winning immunologist Peter Medawar
has called "the most interesting and portentous bio
logical experiment of the 20th century" -the demon
stration that genetic information is carried by DNA.
Launching the Antibiotic Era
In his account of this discovery, The
Transforming Principle, Maclyn McCarty has
described Avery's tenacious genius: "an uncanny abil
ity to ask the right questions [about a scientific prob
lem] and a dogged persistence in finding the answers."
Rockefeller's Rene Dubos also described this talent
in his account of his first meeting with Avery in 1927,
when the two discovered their intersection of interests
over lunch. Dubos told Avery how he had discovered
enzymes secreted by soil bacteria that decompose
cellulose, the polysaccharide that gives plants their
stiffness. Avery immediately remarked that this plant
polysaccharide was related in chemical structure to
the polysaccharide composing the capsule of the most
deadly of pneumococcal strains, called Type III.
"As if by a casual gesture, but in fact deliberate
ly," wrote Dubos, "Avery took from the right-hand
drawer of his desk a little tube containing a white
powder, labeled in his neat handwriting SSSIII, and
shook it in front of me." Still shaking the capsule,
Avery said to Dubos: "This is the polysaccharide of
which the capsule is made. It is completely resistant
to the body enzymes and to all other enzymes we have
used. ...If only we knew of a way to decompose it
with an agent mild enough to be used in the body-an

enzyme, for example-much could be learned about
pneumococcal infections."
Dubos found himself fascinated by this challenge.
A year later, in the summer of 1928, he discovered
an enzyme made by soil bacteria in the cranberry bogs
of New Jersey that could specifically break down the
Type III pneumococcal capsule. The enzyme, called
SIII, cured pneumonia in experimental mice, but it
could not be used in humans because it had to be
injected directly into the lungs. The discovery did,
however, lead to the isolation of more easily adminis
tered antibiotics, and it launched the antibiotic era.
DNA: The Transforming Substance
Also in 1928, the British medical scientist
Fred Griffith discovered a mysterious transformation
that would lead to the most spectacular of the Avery
laboratory's achievements. Griffith injected into mice
Type II pneumococci that had lost the ability to make
a protective capsule; these naked bacteria were harm
less, easily swallowed by immune cells. Griffith simul
taneously injected killed Type III pneumonia bacteria
into the mice-also harmless. Yet the mice died; and
from their bodies Griffith recovered living, and vim-

Above, Transformation of pneumococci from harmless, denuded form
(lefrj to virulent, encapsulated form (righrj studied by Avery, Macleod
and McCarty and published in the 1944 landmark paper.

.....

lent, Type III bacteria.
The dead Type III pneumococcus had not been
miraculously resurrected. Rather, as the Avery lab
soon established, the dead Type III bacteria were
transferring some unknown chemical, dubbed "the
transforming substance," to naked Type II cells that
allowed them to grow a protective Type III capsule.
And the transformed cells
From a purified transforming
passed on this new property
to their descendants.
extract, Avery wrote, "there sep
As Avery had earlier pur
arates out a fibrous substance
sued the chemical composition
of the capsule responsible for
which on stirring the mixture
pneumococcal virulence, so
wraps itself about the glass rod
he and two young colleagues,
like thread on a spool."
Colin MacLeod and Maclyn
McCarty, now sought between
1934 and 1944 the chemical identity of the substance
responsible for this transformation.
"Some job-full of heartaches and heartbreaks,"
wrote Avery in 1943 to his brother Roy, a bacteriolo
gist at Vanderbilt. "But at last perhaps we have it."
From a purified transforming extract, Avery wrote,
"there separates out a fibrous substance which on
stirring the mixture wraps itself about the glass rod
like thread on a spool." The threadlike transforming
substance was deoxyribonucleic acid, or DNA-the
thread of life.

From DNA Back to Infectious Disease:
The Modem Synthesis
Avery, MacLeod and McCarty published their
revolutionary finding in the February 1, 1944 issue
of The Journal of Experimental Medicine. Fifty years
later, this discovery has transformed biological
science. Yet humankind has remained plagued by
infectious diseases, from tuberculosis to the AIDS
virus to a recent outbreak of deadly streptococcal
strains. And it is only relatively recently that the two
strands of the Avery lab's research-in infectious

disease and DNA-are being wound together like the
two strands of the double helix itself.
Studies by Rockefeller scientists and others have
made it clear that the kind of DNA-mediated transfor
mation studied by Avery and his colleagues was no
laboratory curiosity; it is one of several natural mech
anisms bacteria use in their constant struggle for
survival. As antibiotics course through the bodies
of antibiotic-treated humans and animals, the bacteria
living inside evolve and resist these drugs. [See page
20 of this issue.]
Antibiotic resistance has highlighted the need
for vaccines against bacterial pathogens. And here
also the work of Avery and his colleagues continues
to serve as a guiding light. In the 1940s, Michael
Heidelberg and MacLeod-two descendants of the
Avery lab then at Columbia University and New
York University, respectively-developed the first
pneumonia vaccine. The vaccine was made up of
polysaccharides isolated from eight types of pneumo
cocci. Yet with the advent of antibiotics, the use of
this pioneering vaccine was abandoned, although
Robert Austrian of the University of Pennsylvania
School of Medicine, who had worked with MacLeod
at NYU, later led a heroic scientific and public health
effort to develop an improved version. And, in the
late 1960s, Rockefeller Professor Emil Gotschlich
also pioneered a new type of polysaccharide vaccine
against the bacteria that cause meningitis.
Polysaccharide vaccines work by inducing the
body to generate antibodies that bind to specific types
of bacterial surfaces. Such vaccines do not evoke so
called "cellular immunity," however, which is mediat
ed by specialized immune cells called T lymphocytes.
While adults can overcome bacterial infection solely
with antibodies (produced by B cells of the immune
system), children require a T cell response as well.
T cells are unable to recognize a polysaccharide in
isolation; the polysaccharide must be linked, or
"conjugated," to a larger molecule, such as a protein.
The first experimental conjugate vaccine, which
chemically joined a crucial piece of pneumococcus
polysaccharide with the albumin protein of egg white,
was pioneered by Walther Goebel and Avery in 1931.
Yet it was not until 1987 that the first conjugate
vaccine, developed by John B. Robbins and his col
leagues at the National Institutes of Health, was
licensed for clinical use. The vaccine was targeted
against Hemophilus influenza Type B, which infects
1 of every 250 children in the United States, killing
10% of those infected, and leaving another 30% with
permanent afflictions such as blindness or deafness.
Left, M proteins, which shield Group A streptococci from immune cells, appear as hairlike
filaments covering the surface of bacterial cells.

The basis of the vaccine, says Robbins, was laid
in the paper published in 1931 in The Journal of
Experimental Medicine by Goebel and Avery.
No example better illustrates how the twin
strands of the Avery lab's research in infectious disease
and DNA have been fused in modern research than
the work of Rockefeller Professor Vincent Fischetti
on streptococcal vaccines. Streptococci cause not only
strep throat, but rheumatic fever-and in rare cases
of a toxin-producing strep bacteria infected by a
toxin-producing virus, sudden necrosis of the body's
tissue and even death. Following the pioneering trail
of Avery's colleague at Rockefeller, Rebecca Lance
field, Fischetti and his co-workers have studied how
streptococci protect themselves from human immune
cells through surface molecules called M proteins. M
proteins play an analogous role to the polysaccharide
capsule shielding pneumococci; they protect the bacte
ria from engulfment. But the 80 known streptococcal
strains possess 80 different types of M proteins.
After cloning the DNA encoding the M protein,
Fischetti and his colleagues discovered both a region
of the M protein that was shared among the 80 differ
ent streptococcal M proteins and a region common
among nearly all bacteria classified as gram-positive,
which includes the pneumococcus and the bacteria
responsible for staphylococci infections. This latter
conserved region serves to anchor proteins like the
M protein on the surface of the gram-positive bacte
ria. By genetically splicing this anchor sequence along
with the M protein common region into a harmless
bacteria that normally colonizes human teeth and
gums, Fischetti and his colleagues have been able
to design a recombinant DNA vaccine that elicits
antibody production against the different types of
streptococcal M protein. The vaccine, which has
proven to be effective in animal studies, is scheduled
to undergo clinical trials in late 1995.
While conventional vaccines are delivered
through the bloodstream, Fischetti's works at the
mucosal surface-the membranous lining of the diges
tive, respiratory and reproductive system where 90%
of microbial infections begin. Such mucosal vaccines,
says Fischetti, "have changed our thinking, and a lot
of other people's thinking, about how to develop safe
and effective vaccines. If you block the entrance of
the pathogen at the mucosal surface, you can circum
vent all kinds of complications that occur once the
pathogen has entered into the body's tissues."
The conserved M protein anchor region identified
by Fischetti's group has also led them to identify
another possible target for antibiotics, one that would
be effective against all strains of strep and other gram-

positive bacteria. The attachment of M proteins to the
bacterial cell wall requires a specific enzyme; without
this enzyme, the bacteria cannot construct its protec
tive M protein shield. Fischetti's lab is working to iso
late this enzyme. A substance that would specifically
inhibit the function of this essential bacterial enzyme
might serve as a novel type of antibiotic.
The conserved anchor region of the M protein
can also be genetically fused to the DNA encoding a
target protein used by any pathogenic microbe, from
pneumococci to the AIDS virus. "You just cut and
paste DNA," says Fischetti. Hybrid DNA molecules
can then be transferred into a harmless bacteria,
where the target protein of the pathogenic microbe
will be anchored to this innocuous bacteria's surface.
Once introduced into humans, the immune system
will generate antibodies against the target protein
displayed on the surface of the bacteria, providing
immunity against a pathogenic microbe that has
never been previously encountered.
"The investigations carried out by Avery and
his school," wrote Dubos, "have provided the
pattern, the master plan, used by our generation for
the immunochemical study of infectious processes."
With today's ability to read the DNA inside an
infectious microbe to better understand how it causes
disease, and to rewrite DNA to design new drugs and
vaccines, it is clear that Avery's master plan for infec
tious disease research is a legacy that endures. �

Above, Dr. Vincent A.
Fischetti and his col
leagues use recombi
nant DNA technology
to design vaccines
applicable to a wide
variety of pathogenic
microbes.
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got under way.
But despite these exciting
advances, countless questions
remain. How is DNA conserved
and protected within the nucleus?
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Researchers around the world
have been pursuing the thread of
life ever since. In the 1950s, DNA's
double-helical structure was
unveiled. In the '60s, the
genetic code was deciphered
and its mode of translation
into proteins revealed. In the
'70s, the complex nature of
genes in higher organisms
was discovered. In the '80s, the
techniques of genetic engineering
were refined. In the '90s, the effort
to map humanity's entire genetic
endowment began, and the first
experiments in gene therapy

by Susan Blum

processes, including the develop
ment of new life itself? What con
tributions do genes make to dis
ease, and how can those culprit
genes be found?
The answers to these ques
tions - and many more - are
being sought by a new generation
of researchers at Rockefeller, who
continue the legacy of DNA
research begun half a century ago.
Highlighted here is the work of five
of them.
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Telomeres-protein/DNA

After Aveiy and his colleagues dis
covered that DNA carries genetic
information in bacteria, scientists
came to realize that DNA is the
stuff of genes in all creatures,
including humans. In each living
cell, the genes are aligned next
to one another on chromosomes.
Bacterial cells, which have no
nucleus, carry their entire genetic
endowment in one circular chro
mosome. But the genes in the
nucleated cells of higher organisms
are distributed along multiple lin
ear chromosomes-and therein
lie potential problems.
For one thing, the cellular
machinery that duplicates linear
chromosomes in each cycle of cell
division cannot copy their very
ends, thus posing the risk that
the chromosomes will eventually
be whittled right out of existence.
For another, if left unprotected,
the ends of linear chromosomes
are subject to loss through fusion
with one another or degradation
by cellular enzymes that patrol for
dangerous breaks in DNA.
Telomeres-the subject of
study in T itia de Lange's lab
apparently solve both these prob
lems. Telomeres are complexes of
specialized proteins and repetitive
DNA sequences that cap the ends
of linear chromosomes. T hey solve
the "end-replication problem" by
interacting with an enzyme called
telomerase, which adds back the
DNA that would otherwise be lost
when the chromosome is duplicat
ed. And they solve the problem of
potential fusion and degradation by
disguising chromosome ends from
the cell's enzymatic surveillance
mechanisms.
Ironically, the two functions
of the telomeric complex are inher
ently self-contradictory, hiding the
DNA from the patrol enzymes
while handing it over to the telom
erase. Says de Lange, "It's obvious
to most people that the resolution

of this contradiction is going to lie
in the interactions between telomer
ic proteins and DNA." But though
the DNA of telomeres has been
under study for more than fifteen
years, very little is yet known about
the proteins associated with it.
de Lange and her colleagues
are hunting for telomeric proteins
in vertebrates, and so far they have
found two candidates. One might
coat the entire length of the telo
mere; the other recognizes the
repetitive telomeric DNA only at
the telomere's very end.
de Lange is investigating
whether these proteins play a role
in interacting with or regulating
telomerase, an enzyme of intense
interest to cell biologists. Telo
merase is thought to be active in
germ-line cells, the progenitors of
the sperm and egg cells that trans
mit genes to the next generation.
There, the enzyme ensures that
the myriad rounds of replication
involved in producing the cells
do not shave down their precious
genetic inheritance. In most cells
of the body, though, telomerase is
normally inactive, and the chromo
somes are progressively whittled
down.
Some scientists believe this
shortening may trigger the work
ings of a cellular clock that ticks
off the number of cell divisions and
eventually tolls the cell's senescence
and death.
But some cells never die.
These are the cancer cells that
evade mortality and divide prodi
giously, perpetuating their deadly
genetic mutations. At first (as de
Lange discovered while still a post
doc) the chromosomes in cancer
cells shorten with each replication

cycle, just as in normal cells. But
recent studies have shown that at
some point cancer cells turn telom
erase back on, thus stabilizing the
cancer cell's chromosomes and per
haps overriding cellular controls
triggered by ever-shortening
telomeres.
Researchers are hopeful
that drugs against telomerase
might be a new weapon in the war
against cancer-one that targets
cancer cells while leaving healthy
cells alone.
But de Lange points out,
"We need to get down to basics
first. We must understand in detail
what telomeres are to a cell and
what happens to a cell when it loses
them. As long as we don't under
stand that, it's hard to draw any
conclusions about tumor forma
tion, or even about normal aging."
Given the many novel discoveries
that have emerged from telomere
research so far, there may well turn
out to be additional surprises found
lying at what de Lange calls "the
far side of the genome." [!]

Left, Telomeres are complexes of specialized
proteins and repetitive DNA sequences that cap
chromosome ends. In human cells, the character
istic DNA repeat consists of six bases: TTAGGG,
or thymine-thymine-adenine-guanine-guanine
guanine. (The second strand of the DNA double
helix is of course composed of the complemen
tary base partners.) Telomeres are very long;
in humans, they extend for thousands of
base pairs.
Illustration by Terese Winslow
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Perhaps as good a definition of life
as any is that life is order. To per
petuate that order, the information
carried in DNA must be faithfully
transmitted to each new generation
of cells-be they the somatic cells
that make up most of the body, or
the specialized sperm and egg cells
that pass chromosomes on to the
next generation.
The process by which this
order is maintained is the cell cycle
-the tightly regulated sequence
of events in which a cell grows,
duplicates its chromosomes, and
bequeaths them to the "daughter"
cells into which it divides. In the
past decade, research in a wide
range of cells-from those of yeast
to those of vertebrates-has been
converging into a single, highly
unified picture of how the cell
cycle works in eucaryotic cells,
or cells with a nucleus.
Remarkably enough, much of
this progress has occurred through
what Fred Cross calls "a crazy
update" of the experiments con
ducted by Avery and his colleagues
half a century ago. In this modern
version, genes are not transferred
between different strains of the
same species (as Avery did with
pneumococci, for instance) to elicit
new traits in the recipient cells.
Rather, genes are transferred
between cells of species as different
as yeast and humans, where they
are found to perform exactly the
same functions in each. The
reason: The genes are so essential
to the workings of eucaryotes that
they have been conserved virtually
unchanged across billions of years
of evolution.
The genes thus identified code
for proteins that play vital roles
in cell cycle control. Many events
occur in this cycle, which is gener
ally divided into four phases. In the
first phase, G 1 (for "gap l "), the
cell grows and, at a critical point,
commits to reproducing its DNA.

Associate Professor, The Rockefeller University

Once this starting line is crossed,
a slew of events occurs in the next
phase, called S (for "synthesis")
including the replication of chro
mosomes. The second gap phase
(G2) follows, during which the cell
makes another commitmentthis time, to divide in two. After
this critical point, the cell enters
the M phase, named for mitosis
the division of the cell's nucleus
that is one of the last steps leading
up to cell division.
The first insights into control
of the yeast and vertebrate cell
cycle came from studies of the
transition from the G2 to M
phase. Experiments disclosed
how a particular enzyme, a type
known as a kinase, serves as the
master regulator that triggers
mitosis. This molecule is actually
composed of two subunits. The
catalytic part, called a cdk, is pre
sent in constant amounts through
out the cell cycle. But the kinase
can act only when teamed up with
another subunit, called a cyclin,
whose abundance varies at
different times in the cycle.
Later experiments showed
that the same basic scenario works
to regulate events in the transition
between the GI to S phase, when
cdk molecules team up with cyclins
(different from those involved in
the M phase) to orchestrate the
events culminating in chromosome
replication. This cell cycle stage
is the focus of work in Cross' lab,
where he and his colleagues are
studying the function and regula
tion of genes coding for a family
of yeast G 1 cyclins called CLNs.
The cell cycle story has taken
on even greater complexity with
the discovery of proteins in both
yeast and humans that inhibit the
activity of cdk/cyclin complexes.
The first protein ever to be identi
fied as an inhibitor�called FAR 1
-is a yeast protein also under
study in the Cross lab. The

1ne Cell Cf(le

Mitotic kinase triggers
mitosis, or cell division

Mitotic cyclin
breaks down

Mitotic cyclin
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cdk
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G1 cyclin breaks
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Rockefeller researchers' recent dis
covery that levels of FAR 1 rise and
fall cyclically will help further re
fine current models of the intricate
networks controlling the cell cycle.
Today's cell cycle studies may
one day lead to advances in under
standing and treating cancer, a
disease of unrestrained cell growth
and division. Says Cross, "It always
made sense that links would exist
between cell cycle control and
cancer, but only in the past year
or so have those links become real,
rather than speculative." For
instance, one inhibitory protein has
been tied to cellular pathways regu
lated by a tumor-suppressor gene
called p5 3. Researchers have also
learned that the deregulation of
certain cyclin molecules can

Start kinase triggers
DNA synthesis

Above, The cell cycle has four phases: GI
(for "gap I"); S (for "synthesis" of DNA); G2 (for
"gap 2"). and M (for "mitosis," or cell division).
Master molecules called kinases trigger the two
main events of the cell cycle-the duplication
of DNA and the division of the cell into two prog
eny. The kinases are composed of two subunits.
The catalytic parts, called cdks, are present in
constant amounts throughout the cycle. But the
kinases can act only when teamed up with other
subunits, called cyclins, whose abundance varies
at different times in the cycle.
Illustration by Terese Winslow

help transform a normal cell into
a cancerous one. With an ever
increasing understanding of the
intricately choreographed steps
regulating the cell cycle, it may
someday be possible to stop the
music when the molecular dancers
start spinning wildly out of control.
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In the lab of Stephen Burley,

When the seminal paper by Avery
et al. was published, DNA-with
its mere four chemical subunits
was widely believed too "stupid"
a molecule to carry all the informa
tion required to construct and
maintain even the simplest life
forms. But in the two decades
that followed, the wisdom of DNA
was revealed, as researchers deci
phered its code and showed how
genes serve as the blueprints for all
the proteins an organism requires.
In complex multicellular
organisms, every cell possesses a
full complement of genes, but turns
only some of them on. Each differ
ent cell type thus produces a dif
ferent array of proteins. And, as
Stephen Burley explains, it is these
differences in protein content that
make "a liver cell resolutely a liver
cell, a skin cell resolutely a skin cell."
Genes are turned on in tran
scription, the process by which
DNA is read out into a closely
related molecular intermediate
called messenger RNA. (In a later
step, the instructions in messenger
RNA are then translated into
protein.) Transcription is accom-
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plished by complex molecular
machines that forge intricate rela
tionships between DNA, a copying
enzyme called polymerase, and
transcription factors that interact
with the DNA, the polymerase,
or both. Some transcription factors
serve as molecular bookends, posi
tioning the copying enzyme at the
proper place to start a gene's read
out. Other factors act as accelera
tors or brakes, controlling the speed
of transcription and ensuring that
only certain genes are read out in
certain cells.
Burley and his colleagues
explore the workings of these mole
cular machines on an atom-by-atom
basis, using the technique called
x-ray crystallography. T heir studies
of DNA/protein interactions have
disclosed a submolecular world of
astonishing beauty and variety. For
instance, they have shown that TBP,
a positioning factor, sits astride
DNA like a saddle, while HNF-3,
an activating factor, envelopes DNA
with gossamer butterfly wings.
Just as the work of Avery and
his colleagues revealed that DNA
was not as stupid as once believed,
so current explorations disclose that
DNA is not as static as the famous
double-helical structure used to
imply. In fact, crystallographic stud
ies show that DNA may undergo
dramatic conformational changes
when in the grip of the transcrip
tional machinery. For example,
Burley and his colleagues found
that when the TBP saddle drops
over DNA, the DNA twists more
than 100 degrees from its normal
orientation. Likewise, they showed
that some activating and repressing
factors cause DNA to bend and
loop, bringing hitherto-distant
gene regions into close proximity.
Transcription factors can also
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affect DNA's higher organization.
Normally, DNA is spooled around
proteins called histones. Such
packaging corrals the mind-bog
gling six feet of DNA found in each
cell, but it also hinders transcription
by hiding essential gene-control
regions. (Indeed, many scientists
believe that such hindrance by his
tones is a vital component of tran
scriptional control, not merely a
troublesome by-product of a cell's
DNA packaging needs.) Now,
recent studies by Burley and others
are showing that transcription fac
tors can affect DNA/histone inter
actions in ways that alter DNA's
usual patterns of nesting within
the nucleus.
Says Burley, "It is becoming
clear that to know how the right
gene gets transcribed at the right
time, we will have to understand
not only protein/protein and pro
tein/DNA interactions, but the
much larger questions of DNA
structure and organization, as well."
The more scientists learn about
the machinery that controls gene
activity, the better their chances
of eventually tinkering with those
machines for their own therapeutic
purposes.
For instance, part of the
process that turns a cell cancerous
involves the deregulation of tran
scriptional controls. By throwing
molecular monkey wrenches into
transcriptional machines gone
amok, scientists may someday be
able to slow or even halt the pro
gression of cancer. They may also
be able to construct their own
transcription machines from
scratch, to safely and accurately
regulate foreign genes delivered
in gene therapy for a wide range
of diseases. The ultimate goal,
says Burley, is to enlist knowledge
gained from crystallographic studies
"not only to understand transcrip
tion, but actually to control it in
the context of the human body." [!]

How DNA Weaves
the Fabric of Life
Cell

Cells

Cells contain many structures and perform

many functions crucial for life. Their workhorses are
proteins, the molecules that shore up a cell's structure,
control its chemical reactions, and determine which
substances enter and leave.

Chromosome

Chromosomes

Chromosomes are the struc

tures that package DNA, the substance encoding the
instructions for proteins. Some organisms sequester
their chromosomes within a cell nucleus; others do not.

DNA

DNA is a double-stranded helical molecule

composed of four different subunits, or bases Adenine (A), Thymine (T), Guanine (G) and Cytosine (C).
Within the helix, the bases always link up with a partic
ular partner: A pairs only with T, G only with C.

Genes

A gene is an information-carrying segment

of DNA. Genes can be thousands or even hundreds of
thousands of base pairs long. The information in each

Gene --

gene is different, depending on the order in which the
bases are arrayed in the gene. Most genes contain the
information for constructing proteins.

Proteins

Proteins are long chains of amino acids

linked one to another. Different sequences of DNA
bases code for different amino acids. The cell reads out
this code in a series of intricate steps. First, one strand
of DNA is transcribed into a closely related molecular
intermediate called RNA. Then the cellular machinery
translates RNA into proteins. The unique order of bases
characteristic of each individual gene gives each protein
its unique identity. Proteins serve many different func
tions and give cells their essential characteristics.
Illustration by Terese Winslow
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Stephen OiNardo and
co-workers are pursuing
the principles that control
how embryos t

Associate Professor, The Rockefeller University

The genes that get read out into
proteins do more than maintain an
organism's everyday life. They also
control the emergence of new life
itself, in what Stephen DiNardo
calls "the mystique and the magic"
of embryologic development.
Development consists of a
series of choices. The original
fertilized egg has the potential
to become every type of cell the
mature organism will require.
But with each round of successive
cell division, the options for each
daughter cell grow progressively
limited, as the cells make choices
that nudge them closer to their
final identity. These choices are
made manifest in the emergence
of cellular patterns of ever-increas
ing complexity within the embryo.
At each step, the decisions are
dictated by positional information
that tells a cell where it is in rela
tion to other cells in the emerging
cellular pattern.
Researchers in the DiNardo
lab are investigating how positional

information specifies the ten or
so different epidermal cell types in
the fruit fly embryo. Each differen
tiated cell type has a different shape
and boasts a particular surface
appearance. Some cells are smooth,
while others sport a little hair, or
denticle, of a characteristic length,
thickness and orientation.
While a fly's prickly surface
might not seem very aesthetic,
it is yielding elegant information
about embryonic choices-includ
ing some made in the earliest stages
of development.
During that early period,
positional information is conveyed
to a cell from "organizing centers,"
areas that serve as sources of signals
directing the differentiation of
large numbers of cells into many
different cell types.
Scientists have known about
organizing centers since the 1930s,
but the search for the signals they
send has long been fruitless.
Recently, however, researchers
from a number of labs identified
the first such signaling molecules in
vertebrates, and found that they all
belonged to the quirkily named
"hedgehog" family of proteins.
Though these discoveries were
loudly trumpeted in the press, the
initial identification of the hedge
hog gene, and of the crucial role it
plays in development, was actually
accomplished in the mid-1980s
in work done in the fruit fly.
That hedgehog genes are proving
important in so many different
species comes as no surprise to
biologists, who keep finding that
the fundamental principles-and
molecules-controlling develop
ment are the same in all animals.
Many significant findings
about hedgehog proteins in fruit
flies are being made in DiNardo's
lab, where he and his colleagues are
studying the role of hedgehog and
another protein called wingless.

Their research has disclosed a
two-phase process of interactions
between cells that express either
hedgehog or wingless. In the first
phase, these cells signal each other
over short distances to stabilize
hedgehog and wingless production.
This stabilization creates two
organizing centers that serve as
continuous sources of hedgehog
and wingless proteins, which then
act over a distance to specify the
fate of several different epidermal
cell types.
DiNardo believes that this
two-phase model will prove to be,
a general one, not only in flies but
in vertebrates, too. But while the
overall plot line may stay the same,
the players will vary. In both flies
and vertebrates, although a limited
number of conserved families of
signaling molecules keeps turning
up (including hedgehog-type mole
cules and wingless-type molecules)
they interact with each other in
various combinations.
DiNardo is not disconcerted
by these variations. "There will
be perhaps three or four different
ways in which molecules like
hedgehog can act, and nature will
use them at different times and in
different places in the development
of different organisms," he says.
Insights like these would not
have been possible without the
revolution begun by Avery and his
colleagues. Before then, develop
mental biologists were limited to
observing the effects of positional
information by moving various
parts of tissue around in the
embryos of animals such as chicks
and frogs. Today, researchers can

also use the powerful tools of
genetics in invertebrates such as
flies and worms, and then analyze
the function of those genes directly

Above, Each different cell type in a fruit fly's
epidermis has a different shape and appearance.
Some are smooth, while others sport little hairs
of various lengths, thicknesses and orientations.

in virtually any species, using the
techniques of molecular biology.
As their studies continue to disclose
the essential mysteries of develop
ment, and the fundamental similar
ities of this process in all organ
isms, it is clear why DiNardo
says, "This is really a very
exciting time." �
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Half a century has passed since Avery
and his colleagues showed that the
secret oflife lies in DNA. But until
very recently, most of those secrets
lay tantalizingly out of reach, due to
a lack of lures and hooks with which
to fish out individual genes from the
ocean of DNA possessed by each
organism.
Within the past decade, howev
er, molecular biology has provided
the tools that let scientists identify�
and analyze individual genes of inter
est. As the newspaper headlines
attest, some of the genes of greatest
interest are those that, singly or in
combination, cause or contribute
to the many diseases that plague
mankind. Among those diseases is
obesity, a condition associated with
such potentially life-threatening
health problems as diabetes and high
blood pressure. Recently, Jeffrey
Friedman and his colleagues took
a major step toward identifying one
of the genetic contributors to obesity
by cloning-or pulling out from the

chromosomes-a gene, called ob,
that may play a central role in weight
control.
Studies have shown that from
60 to 90 percent of the differences
in people's weights is due to their
genes. For many years, researchers
had hypothesized that these genes
play roles in a complex feedback
system that maintains body weight at
a particular set point. Such a system
would involve signals from points
in the body's periphery (the fat cells,
for instance) that reach receptors in
a brain region called the hypothala
mus (and perhaps elsewhere, too)
to report on how much the body
currently weighs and how well it
has recently been nourished. T he
brain in turn would regulate various
responses-such as energy expendi
ture and food intake-to keep body
weight steady. In such a complex
system, problems anywhere along
the pathway-a faulty signal, for
instance, or a defective receptor-.
could lead to obesity.
To clone the genes involved
in this system, researchers turned to
the laboratory mouse, a genetically
well-understood creature in whom at
least five different genes are known
to cause obesity in various strains.
Friedman and his colleagues set their
sites on finding two of these genes:
ob (or obesity), which previous stud
ies had indicated might code for the
signaling molecule, and db (or dia
betes), which appeared to code for
its receptor.
By employing a method called
"positional cloning," Friedman and
his colleagues recently cloned the
mouse ob gene. (See "How to Find
a Disease-causing Gene," right).
Subsequent analysis of the gene has
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provided much evidence suggesting
that ob may indeed code for a signal
ing molecule, produced by fat cells,
that sends a message to the hypothal
amus to reduce food intake and/or
boost energy expenditure once the
fat cells have reached a certain mass.
Experiments to confirm ob's signal
ing role are now under way in
Friedman's lab, as are studies to
positionally clone the db gene.
Friedman and his colleagues
have found that the ob gene is
conserved, or similar, in many verte
brates from eels to humans, whose
ob gene shares an 84 percent similar
ity to that of the mouse. Such con
servation suggests that a feedback
system for weight maintenance has
been in place for eons, and that the
genes controlling this system have
been subjected to intense selective
pressure.
"Humans evolved in an environ
ment where getting enough calories
was difficult, so selection might have
favored versions of the genes that
allow us to deposit food efficiently
as fat," Friedman says. Once highly
adaptive, these versions of the genes
would now be maladaptive in envi
ronments such as the United States,
where sufficient calories are avail
able to many-and where the rate of
obesity has soared to 30 percent.
Some of the strongest evidence
in support of evolutionary pressure
on weight maintenance genes comes
from studies of aboriginal popula
tions such as the Pacific Islanders of
Micronesia, who now have extremely
high rates of obesity and diabetes.
"In general, the more severe the
environmental conditions in past
history, the more profound the obe
sity in modem times," Friedman
says. Studies of such populations
offer extraordinary opportunities to
answer the fundamental question
about genes like ob, to wit: Is their
role in human obesity as clear as
their role in the rodent form of the

disease? Friedman and his colleagues
are now collaborating with residents
of the Micronesian island of Kosrae
to answer this question.
The confirmation of ob's role in
human weight maintenance would
open up many exciting possibilities
for a "more rational approach for

devising novel therapies for weight
disorders, " Friedman says. Such
therapies could be used not just to
lower weight in the obese, but also to
boost it in those who are profoundly
underweight due to conditions such
as cancer and AIDS. �

How to Find a Disease-causing Gene
1 . Find DNA Markers

Markers are DNA sequences
that lie close to a particular gene and are inherited with it.
By analyzing how various DNA markers are inherited
among members of a family in which the disease some
times occurs, scientists can identify markers flanking the
disease-causing version of the gene. This pinpoints the
DNA region in Which to look for the gene itself.

2. Assemble Physical Map

a
A physical map
tells scientists how much DNA lies in the region between
the markers, and makes further molecular analysis of the
DNA possible. To create the map,
DNA in different parts of the region is cloned, or
reproduced, in vectors such as bacteria or yeast.
These cloned DNA segments can then be aligned
by identifying regions of overlap.

Marker A: Inherited with
the disease-causing gene
in the family under study

Marker B: Inherited with

�
Disease-causing gene lies somewhere
in this region of DNA

Marker A

Marker B

DNA clone #1

0(:)0(_

DNA clone #2

�

DNA clone #3

�

3. ldenti& All the Genes

More than one gene
may lie in the region, and scientists must identify all
of them before homing in on the one causing disease. Only
some of the DNA in the region makes up genes;
the rest is DNA with no known function. The genes are
identified using various biochemical tricks to separate the
genes from the rest of the DNA.

Marker A

Marker B

��x::x
Gene A

4. Sequence and Compare Genes

A11 DNA
is made up of just four bases, or subunits. Each gene
differs from all others in the particular sequence in which
those bases appear. The base sequence for each gene in
the region can be determined, and then compared with
the sequence of the same gene as it exists in people with
out the disease. Mutations in a gene from a person with
the disease identify tbat gene as the culprit.

DNA clone #4

Gene B

Gene C

Genes of healthy person

>or'��
GeneC�
Gene A

"GenW

'

Genes of person with disease
mutation

Gene A

Gene B

Gene C
Illustration by Terese Winslow

SClfNCf AND PUBllC HfAlTH

by Doron Weber
During the past four to five years,
resistance in the United
medical practitioners, microbiolo
States range as high as $30
Sounding the
gists and public health profession
billion. Tomasz believes it is
Alarm on Antibioticals all over the world have begun
imperative
for
basic
to voice concern over the alarming
researchers
and
public
policy
resistant Bacteria
increase in the number of disease
makers to join ranks now,
ca using micro bes that have
before the cost in dollars is
become resistant to drugs that once checked them.
dwarfed by the rising toll in human lives.
"Antibiotic-resistant bacteria are already involved
Spreading Multiresistance
in the spread of hospital-acquired diseases such as
Tuberculosis, once thought to be a plague of the
pneumonia, bloodstream and wound infections, and
past, returned during the 1980s armed with resistance
in community-acquired diseases such as tuberculosis,
to several previously effective antibiotics. By 1992,
meningitis, lung and middle-ear infections across
strains
of tuberculosis appeared that were resistant to
America," says Professor Alexander Tomasz, head of
most
of
the 12 potentially usable drugs in existence to
Rockefeller University's laboratory of microbiology
treat
it.
and a world-known authority on bacterial antibiotic
Tuberculosis is only the most well publicized of
resistance.
the returning, newly resistant plagues. In 1992, over
"As more and more common bacteria acquire
19,000 patients died in the U.S. of various bacterial
resistance genes, many of the diseases we thought we
infections acquired while in the hospital; and a large
had under control are coming back. We are looking at
proportion of the microbes that most frequently cause
a problem with the potential for causing a public
these infections have become resistant to antibiotics,
health crisis."
according
to the Centers for Disease Control. T he
Already, estimates of the annual cost of antibiotic
Above, Strand of DNA entering a pneumococcal cell. Inset, Rockefeller
Professor Alexander Tomasz points out the dangers of antibiotic-resistant
bacteria at a lecture organized by the Public Health Research Institute and
sponsored by Lederle Laboratories.
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available data indicate that this problem will only get
dish exuded a substance, called penicillin, that killed
bacteria, penicillin and its descendants became miracle
worse.
For example, almost half of all the hospital iso
drugs. But man's victory over microbes proved short
lates of the bacterium Staphylococcus aureus have
lived. While most bacteria will succumb to a powerful
become resistant to the most useful penicillin-type
new antibiotic, a few have genes, or genetic muta
antibiotics. T his bacterium is the most frequent cause
tions, that enable them to resist the antibiotic attack,
of wound, lung and bloodstream infections acquired
and these produce resistant descendants. So only the
in the hospital; and there are many strains of staph
fittest-that is, the most resistant-bugs survive. Each
against which there now remains only a single effec
surviving bacterium can leave over 16 million off
tive antibiotic, called vancomycin. Moreover, the
spring within 24 hours.
genes for resistance, which reside in bacterial struc
"On an evolutionary scale, bacteria and host have
tures or loops of DNA called plasmids, can be passed
been facing each other and eoexisting for billions of
on not just to their progeny but also to bacteria of dif
years" explains Tomasz. "The discovery of antibiotics
ferent species.
introduced a radically new element into this face-off.
A similar scenario is emerging among pneumo
T he devastating effectiveness of penicillins and other
cocci, one of the most frequent causes of community
drugs introduced during the 1940s forced the micro
acquired diseases, particularly in small children.
bial world to mobilize its genetic resources. Today,
Pneumococcus is currently responsible
after only 50 years-an incredibly
for tens of thousands of bloodstream
short span on the evolutionary time
Today, after only
infections, 500,000 new cases of pneu
scale-bacteria have developed a
50 years-an
monia and 6 million new cases of mid
remarkable variety of mechanisms to
incredibly short span
dle-ear infections each year in the United
resist every known usable antibiotic."
on the evolutionary
States.
T he most dangerous are bacteria
time scale-bacteria
"We now have several case descrip
that seem to be able to collect many
tions from the U.S. of infants with
mechanisms of resistance and can thus
have developed a
meningitis caused by resistant pneumo
gradually become resistant to all
remarkable variety of
cocci who are no longer responding to
antibacterial agents. And these resis
mechanisms to
therapy by penicillins and cephalo
tant
genes can be spread, transferred
resist every known
sporins," says Tomasz. As a result, doc
from one species to another, and then
usable antibiotic."
tors have had to use vancomycin, the
jet from one part of the world to
same drug that has become a "last
another.
resort" antibiotic against staphylococci as well. In at
"Drug-resistant bacteria can spread geographical
least one of these cases, the meningeal disease left the
ly," says Tomasz. "The rule seems to be that wherever
a resistant strain is reported in one part of the world,
infant neurologically devastated.
To make matters even worse, the genes providing
as time goes by it will find its way to other parts of
bacteria with resistance to vancomycin are already
the world." For example, Tomasz's lab, a world
present in yet another hospital-borne pathogen called
leader in molecular epidemiology (a method that can
Enterococcus faecium. Dr. Sandra Handwerger, clini
identify the offspring of resistant bacteria through
cal scholar and assistant professor in the Tomasz
DNA-level fingerprints), helped track the movement
lab-and one of the first to identify the biochemical
of multiply resistant clones of pneumococci: One was
basis of vancomycin resistance-shares the worry of
tracked between Iceland and Spain where vacationing
most biochemists that these resistance genes will find
Icelanders may have unknowingly picked it up.
their way into the already multiresistant and highly
Another clone, most likely originating in Spain, was
virulent strains of staphylococci and pneumococci,
tracked literally all around the globe-to Portugal,
France, Croatia, South Korea-and this pneumococcal
posing a potentially alarming scenario for hospital
patients. If vancomycin fails, there is no drug current
clone has now spread widely across hospitals and day
ly available to stop these bacteria. "Many people,"
care centers in the U.S.; the carriers may have been
Tomasz argues, "feel that such an event will bring us
unsuspecting travelers.
close to a post-antibiotic era."
Travel, tourism and migration have made antibi
otic resistance a potential worldwide threat to public
health. Tomasz argues that we have to "rethink and
Post-Antibiotic Era
For a brief, heady period after Alexander Fleming
renegotiate" our whole relationship to the procaryotic
first found in 1928 that a colony of mold in his lab
world.
11

Alex Tomasz1 A lifelong
Scientific Commitment
Born in Hungary, Tomasz was studying biology
and chemistry at the University of Budapest when he
was forced to flee the country after the Soviets
cracked down on the Hungarian uprising in 1956. He
arrived in New York penniless, and took a job as a
technician at Sloan-Kettering Institute before earning
a Ph.D. in biochemistry at Columbia University. Upon
graduation, Tomasz, who was interested in molecular
genetics and the surface of bacterial cells, decided to
focus on how pneumococci manage to capture and
internalize DNA molecules during the process known

Above, Tomasz ponders a puzzling epidemiological triangle-a high degree of
antibiotic resistance goes with a low degree of genetic diversity among the
bacterial isolates-as he stands before a blackboard in his laboratory.

as genetic transformation.
Pneumococcus has the capacity, rare among bac
teria, to take up free-floating strands of DNA from its
environment. It was this capacity, dubbed "compe
tence," that enabled the Avery lab to identify DNA as
the carrier of genetic information in its landmark
1944 paper. Well over a decade later, Tomasz knew
there was still only one place to study this phenome
non: T he Rockefeller University laboratory of Rollin
Hotchkiss, whose group had made enormous
advances in elaborating on the discovery of Avery,

dations, the report called for greater awareness of the
MacLeod and McCarty.
problem among clinical microbiologists, government
After joining the Hotchkiss lab, Tomasz began to
health authorities and physicians; increased funding
study how the pneumococcus bacterium can recognize
a DNA molecule in its vicinity. Through what signals
for basic research into the mechanisms of resistance;
more adequate surveillance systems for tracking the
does this recognition take place? Among his major
spread of resistance; and a fast track for new antibac
findings, Tomasz discovered that competent cells of
terial agents so that they become available for com
the pneumococcus release a protein he called "activa
passionate use in emergency situations.
tor" that could induce the uptake of DNA in cells
that were not yet competent. The discovery of the
In December of 1993, Tomasz moderated a New
York Academy of Medicine conference addressing
activator, the first bacterial hormc;me, and the subse
antibiotic resistance in New York City clinics and hos
quent studies on the DNA-bindirig transport system
pitals. T he leading participants-who included Dr.
were, in a sense, a completion of Dr. Avery's discovery
Richard Roberts of New York
of transformation. Over the fol-'
Hospital and Dr. Barry Kreisworth
lowing years, studies in the Tomasz
I n July 1993, Tomasz
of the Public Health Research
lab have contributed richly to �1
organized a one-day
Institute, as well as officials from
wide range of topics in microbiolo
workshop at Rockefeller
the New York City Department of
gy, such as the chemistry and bio
that brought together some
Health-felt such a sense of
logical activities of bacterial cell
of the nation's leading
urgency that, one month later, in
walls and the mode of action of
infectious disease experts
penicillin; they have identified the
January, they formed the Bacterial
including those from the
Antibiotic Resistance Group
molecular basis of beta lactam
(BARG). T he aim of BARG, a
resistance in pneumococci and
CDC, the FDA and the NIH,
grass-roots
collaboration of the
staphy lococci; and discovered
as well as the presidents of
public
and
private
sectors, is to
antibiotic tolerance or the ability
several scientific and
accurately tally antibiotic-resistant
of bacteria to survive antibiotic
medical organizations.
bacteria in New York City ; to
treatment despite being neutral
improve infection control; to enlist
ized. Most recently, the lab's
the pharmaceutical industry and the Environmental
efforts have led to the elucidation of a large number of
Protection Agency; and to disseminate the techniques
auxiliary genes needed for antibiotic resistance, genes
of molecular epidemiology to New York City
that may be new targets for pharmaceutical drugs.
hospitals.
The Tomasz lab also pioneered in the use of molecular
In February, Tomasz flew to San Francisco where
"fingerprints" for tracking the movement of drug
his presentation o n "Disease-ca using Bacteria
resistant bacteria in hospitals in the U.S. and Europe.
Resistant to Antibiotics" was the most talked-about
lecture at the annual meeting of the American
Getting the Message Out: A Busy Year
Association for the Advancement of Science.
W hile his lab continues to study basic problems in
Tomasz's warning about resistance became the num
microbiology, Tomasz has begun to organize a public
ber one story to emerge from the conference, reaching
response to the emergence of disease-causing bacteria.
an estimated audience of 42 million people world
In July 1993, Tomasz organized a one-day work
wide. Coverage was so widespread that Washington
shop at Rockefeller that brought together some of the
began to pay attention, and in March, Tomasz was
nation's leading infectious disease experts including
contacted by the Office of Technology Assessment to
those from the CDC, the FDA and the NIH, as well as
help them prepare a report to Congress on the public
the presidents of several scientific and medical organi
health dimensions of bacterial antibiotic resistance.
zations. They focused on the accelerating spread of
Tomasz has been active internationally as well.
pathogenic bacteria resistant to antibiotics and asked
Together with his friend, the South African scientist
whether multiresistant bacteria posed a threat to pub
Keith Klugman, he organized 1n April of last year a
lic health in the United States. T he resounding
conference in Prague focusing on the multidrug-resis
answer, they all agreed, was "yes."
tant pneumococcus in Eastern Europe. Tomasz, who
Nine months later, the April 1994 issue of the
had marshaled a network of investigators to collect
New England Journal of Medicine published the pro
data on resistance in the former Eastern Bloc coun
ceedings of the workshop in a special report entitled
tries, found signs of increasing resistance in Hungary,
"Multiple-Antibiotic-Resistant Pathogenic Bacteria"
Croatia, Bulgaria and Slovakia.
that was authored by Toma_sz. Among its recommen-

Above, Dr. Tomasz surrounded by some members of the microbiology
laboratory who hail from 11 countries.

A few days later in May, while still in Prague,
Tomasz was a plenary speaker at the International
Society of Infectious Disease conference addressing
the global threat posed by bacterial resis
tance. Both Prague meetings were stand
Instead of
ing-room-only events, generating much
indiscriminate killing
professional interest.
In July, Tomasz, along with Nobel
with drugs, which inspires
laureate, Rockefeller University professor
germs to develop and
and former president Joshua Lederberg,
share new resistance
was asked to serve on a new task force on
antibiotic resistance organized by the
strategies, more
American Society of Microbiology.
selective approaches
Lederberg was coauthor of the seminal
are called for.
1992 National Academy of Sciences
report, "Microbial T hreats to Health in
the United States," which first brought
national and international attention to the larger
issues of pathogenic microbes. Lederberg's laboratory
was also one of twelve at Rockefeller that joined with
Tomasz to start a new campus research initiative on
microbial antibiotic resistance and disease.

New Hope: Back to the Future
The aim of the new Rockefeller research program
that Tomasz has proposed is to develop knowledge
and strategies for combating the five types of resistant
bacteria that pose the greatest threat to public health:
tuberculosis, Staphylococcus aureus, coagulase-nega-
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Above, Worldwide spread of a multiply drug resistant clone (capsule type
23F) of pneumococcus, probably originating in Spain. Using molecular "fin
gerprints" to identify the offspring of drug-resistant pneumococcus, the
Tomasz lab has helped track the disease-causing bacteria all over the globe.

tive staphylococci, pneumococci, and enterococci.
"Such a program should revitalize interactions
among laboratories with complementary skills," says
Tomasz. "It will also provide the structure for a mod
ern and exciting interdisciplinary training program for
graduate and postgraduate trainees. In addition, clini
cal research in antibiotic resistance will be expanded
at T he Rockefeller University Hospital." T he plan
also includes studies in the molecular epidemiology of
resistance to be conducted in collaboration with sever
al hospitals in the U.S. and abroad.
It is no coincidence if the mission behind these
initiatives sounds familiar. As Rockefeller University
President Torsten Wiesel told participants at the July
1993 workshop, it was the deadly epidemics of infec
tious diseases that prompted the foundation of The
Rockefeller Institute for Medical Research in 1901 as
the nation's first biomedical research center. "The
founders of the Institute understood clearly that the
ultimate control of these devastating microbial dis
eases required first that scientists turn their attention
to the understanding of the nature and mechanism of
infectious disease," said Wiesel. It will be the mission
of modern microbiologists at Rockefeller and else
where, he emphasized, to readdress themselves to this
public health issue now, with emphasis on antibiotic
resistant microbes that cause invasive diseases.
Tomasz believes that the best hope lies in rethink
ing our entire approach to treating infectious diseases.

Instead of indiscriminate killing with drugs, which
inspires germs to develop and share new resistance
strategies, more selective approaches are called for.
"For example, you could aim drugs at the specific dis
ease-causing components of the bacteria, or at the
dangerous response they provoke in the host," he sug
gests. "The result would be more selective, lower pro
file drugs that would threaten a bug's bad habits
rather than its survival, making the drugs far less like
ly to become sitting ducks for resistance." Tomasz is
convinced that the design of such future drugs will
require that the pharmaceutical industry develop close
alliances with microbiology laboratories studying
mechanisms of bacterial physiology, gene transfer and
disease.
In his own efforts to find new molecular strategies
that can be mobilized against bacteria, Tomasz has
reinstated studies in his lab on genetic transformation.
So he, and other pneumococcal researchers at
Rockefeller, have truly come full circle. Pneumonia,
the leading killer at the beginning of the century, led
to Avery's pioneering work on pneumococcus and the
discovery that genes are made of DNA. Now DNA
techniques are helping Tomasz and others study the
pneumococcus with greater precision in an attempt to
better understand antibiotic resistance and conquer
pneumococcal disease. Says Tomasz, "That incredible
little bug, the pneumococcus, still has many lessons to
teach us." �
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quality of life as we know it.''
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and disease.''

David Rockefeller

1994

chairman of the Executive Committee
of the Board of Trustees,
The Rockefeller University

1985

Nobel laureate, immunologist

grammar of biology....Avery gave
us the first text of a new language,
or rather he showed us where
to look for it.''

Erwin Chargaff

1971

professor emeritus,
Columbia University

le discovery
biological evolution which continues
to transform our view of nature in
its most intimate details ....''

1985

Lewis Thomas

physician, scientist and essayist

November 19, 1993
James D. Watson, Nobel laureate
and director of the Cold Spring
Harbor Laboratory, launches the
celebration with a public 1ecture
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December 29 & 30, 1993
Above, as part of a year-long focus
on DNA research, molecular
DNA researchers John Kuriyan
and Stephen K. Burley discuss
"da Vinci and Darwin and the
Molecules of Life" at the annual
Alfred E. Mirsky Christmas Lectures.

le
February 3, 1994
Nobel laureate Alfred Day Hershey,

left, and Professor Emeritus Rollin
Hotchkiss were among six pioneers
active in the field of genetic
research between the publication
of the Avery paper and the discov
ery of the double-helical structure
of DNA who gathered for a round
table discussion. The others were

nome

Visiting Professor Robert Olby,
chair; Professor Joshua Lederberg;
Professor Emeritus Maclyn

February 2, 1994

McCarty; Erwin Chargaff; and

David Botstein, professor

Seymour Cohen.

and chair of the genetics
department at Stanford University,
d�livers a public lecture on the
Human Genome Project.

February 1, 1994
On the anniversary of the publication
of the landmark paper, Professor
Emeritus Maclyn McCarty, center,
the sole surviving member of the
Avery team, is honored in the RU
Hospital by, from left to right, Deputy
Mayor of New York City John Dyson,
Chairman of the Board's Executive
Committee David Rockefeller,
President Torsten Wiesel, and
Physician-in-Chief Jules Hirsch.

ation
May 6, 1994
Professor Jan Breslow, above,
chairs a scientific symposium
featuring lectures by a new genera
tion of DNA researchers at the
university: Professor Stephen K.
Burley, Associate Professor
Frederick Cross, and Associate
Professor Jeffrey Friedman.

April 18, 1994
Nancy Wexler, professor at
Columbia University and chair of the
Human Genome Project's Committee
on Ethical, Legal, and Social Issues,
speaks on DNA technology and its
consequences at a public lecture.

of
February 4, 1994
Professor Emil Gotschlich,
center, chairs a scientific sympo
sium that features Robert Austrian
of the University of Pennsylvania
School of Medicine, left, and John
Robbins of the National Institutes
of Health. The symposium reviewed
Avery's scientific accomplishments
and subsequent developments in
the fields of immunology and
infectious disease.

identified
genes: clockwise,
Oswald T. Avery,
Colin MacLeod and
Maclyn McCarty.
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Nancy Wexler's
for the

Huntington's Disease Gene
By Mika Ono Benedyk

The 1944 Avery paper did not just usher in a new era 'of molecular biology and genetics.
The revolution in lmowledge also created a host of new ethical dilemmas never encountered before.
As part of its "50 Years of DNA" celebration, The Rockefeller University invited renowned
Columbia professor and bioethicist Nancy Wexler to discuss some of the personal and ethical rami
fications of our brave new genetic world.

Of all possible fates,
having the genetic disorder that
causes Huntington's disease is one
that no person would choose. The
symptoms, which usually set in at
mid-life, are subtle at first: lack of
coordination, small twitches, memory
loss, depression, irritability. But as
the disease progresses-over the
course of 10 to 20 agonizing years
part of the brain inexorably degener
ates. Those afflicted lose the ability
to control their movement and their
arms and legs flail about wildly.
Near the end, and the end is inev
itably death, patients are emaciated,
incontinent, unable to speak, yet still
able to grasp the tragedy of
their demise.
Nancy Wexler, who spoke
at The Rockefeller University in
April as part of its 50th anniversary
celebration of the discovery there
that genes are made of DNA, has
been at the forefront of bringing
modern genetic technology to
bear on this disease. Her work
helped to find a genetic marker for
the illness, and then to identify
the genetic defect that causes
Huntington's disease. While these
discoveries have brought new
hope for a cure, they have also
brought agonizing new dilemmas
for society.

A

Personal Quest

When Wexler was 2 3, she
learned that her mother, like three
of her uncles and her grandfather,
had Huntington's disease. In itself
the news was devastating. But it also
had implications for her sister and
herself: it meant that they each had
a 50 percent chance of developing
the illness themselves later in life.
The days-and years-after
Wexler's mother's diagnosis were try
ing. Wexler and her sister decided
immediately never to have children.

When Wexler was 23,
she learned that her mother,
like three of her uncles
and her grandfather, had
Huntington's disease.
Wexler battled depression. But
everyone in the family also became
passionately committed to the strug
gle against the disease.
Wexler, who had just graduated
from Radcliffe, continued with her
plans to pursue a Ph.D. in psycholo
gy, focusing on families with
Huntington's. After graduating from
the University of Michigan in 1974,
she moved to New York to teach and
open a private practice. It wasn't long

before she was appointed executive
director of Congress's Commission
for the Control of Huntington's
Disease and Its Consequences. After
the commission's work was over, she
became a health science administra
tor heavily involved in Huntington's
issues at the National Institute o{
Neurological, Communicative
Disorders and Stroke.

T

he Search
for the Gene

Wexler had great faith that DNA
could provide the clue to curing
Huntington's disease. She felt that
finding the gene would lead directly
to a treatment. But for many years,
the task seemed Herculean: Hunting
ton's disease could be caused by a flaw
in any one or several of the 3 billion
base pairs in the human genome.
Then, in the early 1980s, fresh
hope appeared. David Botstein (who
also spoke at Rockefeller as part of
the "50 Years of DNA" celebration)
and his colleagues had developed a
hypothesis that variability in the
DNA close to a disease-causing gene
could be used to demarcate the gene's
approximate location. Disregarding
the warnings of many reputable sci
entists that finding a marker could
take over half a century, Wexler
pushed ahead.

Mika Ono Benedyk, a writer, works
at the Rockefeller Group.

The search took her to the shores of
Lake Maracaibo, in Venezuela.
There, in several small, poor fishing
villages, lay one of the largest com
munities in the world afflicted with
Huntington's disease. Throwing
themselves into the quest, Wexler and
her colleagues built a pedigree of
almost 13,000 people and collected
blood samples which would come to
number over 3,000. Jim Gusella at
Massachusetts General Hospital, who
was also studying a family with
Huntington's from Iowa, extracted
the DNA from the Venezuela samples
and looked for a genetic marker that
"traveled" with Huntington's disease
in a family.
In an incredible stroke of
luck, the Gusella lab together with
P. Michael Conneally of Indiana
University stumbled upon a mark
er on the 12th try. Almost all those
with Huntington's disease had one
form of the marker while their
healthy relatives had another. Wexler
was jubilant. The location of the
probe was quickly mapped to the top
of the short arm of chromosome 4,
and the results were published in
Nature in November 1983, just three
years after the effort began.

E

ureka!

The next goal was to find
the exact location of the gene,
isolate it and learn its secret-what
Wexler at first assumed would be
a quick and easy task.
Wexler helped marshal the
forces of six scientific groups around
the world to collaborate instead of
Above. Nancy Wexler sits behind a sculpture of the
DNA double helix. Right. Wexler's quest for the
gene that causes Huntington's disease took her to
Lake Maracaibo in Venezuel,p, one of the largest
communities in the world afflicted with the disease.

compete in their search for the gene,
a highly unusual effort in the often
cutthroat arena of science. The
groups were led by: Francis Collins
of the University of Michigan;
Hans Lehrach of the Imperial
Cancer Research Fund, London;
Peter S. Harper of the University
of Wales College of Medicine;
David Housman of the Massachusetts
Institute of Technology; Gusella; and
John Wasmuth of the University of
California, Irvine. One year stretched
into two, then three... Almost 10
years passed without isolating the
gene. Some scientists speculated that
there was no Huntington's disease
gene. Wexler likened the effort to
"crawling up Mount Everest."
The Gusella group was focus
ing on one region of the chroma-

some as part of the collaborative
effort. One night, Marcy Mac
Donald and Christine Ambrose of
Gusella's lab discovered the end of
a gene where there were 48 repeats
of one sequence of nucleotide bases
in a DNA sample from a Hunting
ton's disease sufferer: cytosine,
adenine, guanine (CAG). They
checked against a sample from
someone without Huntington's:
There were only 18 repeats of this
sequence. Could it be so simple?
Soon, the researchers were calling
Wexler with the good news: They
had found the long-sought gene.
Wexler is still filled with wonder
at the finding. "It strikes me as stag
gering the enormously subtle differ
ence between life and death," she
said. "If you have 11 to 34 repeats

of this CAG, you are going to live.
If you have 3 more, from 3 7 to 100,
you are dead."
The researchers also found that
the youngest victims had the most
repeats (although the oldest did not
have the fewest), and that the number
of repeats tended to expand slightly as
the gene was passed from generation
to generation. The Huntington's
Collaborative Research Group
published their conclusions last
year in the journal Cell.

T

he Dilemmas
of Testing

Although from a scientific
perspective the advances in
Huntington's disease have been
astounding, from a medical point
of view little has changed. There
is no cure. There is no treatment.
There is now only a genetic test
that can tell individuals, before they
develop symptoms, whether they
will come down with the disease at
some undetermined time later in life.
The test itself poses new dilemmas

for those at risk for the disease.
"When [the test] first became
available, my sister, father and I had
no question about taking it," said
Wexler in an interview with Columbia,
the magazine of Columbia University
where Wexler is now a professor. "My
sister and I thought, 'Isn't this fantas
tic!' We could have children! My
father could stop saving money for

Soon we will all be facing the
question of whether we want
to know what is ahead in our
own and our children's future.
nursing homes and retire. When we
thought more about it, however, my
father was the first to say, 'Wait a
minute! I don't want to know if either
of you has a bad outcome. One bad
outcome and we're all three dead."'
As Wexler acknowledges, there
are many compelling reasons for
those at risk to take the test. The
absence of the Huntington's gene

Above, Wexler hugs a Venezuelan child who
carries the Huntington's gene.

would be a tremendous relief. Even
if the results show the presence of
the genetic defect, one's family,
career and finances could more
easily be planned.
On the other hand, the reasons
for not taking the test can be just as
compelling. To learn that you have
the Huntington's gene and will die
an early and prolonged death can be
devastating for you and your family:
Some who have tested positive have
attempted suicide. And even a posi
tive result leaves uncertainty: You do
not know when the disease will begin
its insidious advance. In fact, some
individuals who know they have the
genetic mutation begin to think of
themselves as sick before they come
down with symptoms, adopting a
"sick identity" in the face of the
agonizing ambiguity about when
the disease will strike.
Even individuals who test nega
tive are not always as euphoric as

they had thought they would be.
They may feel guilty that siblings and
parents have the Huntington's gene
when they don't. Or they may have
built their identities around being at
risk-abandoning commitments, for
going children, living life in the fast
lane-and be unprepared to learn that
they are ordinary, vulnerable to other
diseases, and responsible for their lives
and futures.
The prenatal test for Hunting
ton's poses a similar dilemma. On
the one hand, you can have a fetus
tested for the Huntington's gene so
that you won't bring children into
the world who will later develop
the disease. On the other, there is
no medical justification to take the
test unless you are willing to abort
a fetus with the genetic flaw.
Underlining how personal and
difficult these dilemmas are, Wexler
will not say whether she has taken the
test for the Huntington's gene, only
that these decisions are complex and
can change given different circum
stances and period in the life cycle.
The genetic underpinnings of
more and more diseases, such as heart
disease, diabetes, colon cancer and
breast cancer, are being revealed. For
some of these diseases, early diagnosis
can prove lifesaving. Soon we will all
be facing the question of whether we
want to know what is ahead in our own
and our children's future, and whether
we can do anything to change it.

A

New Framework
is Needed

A cure for Huntington's, and other
genetic diseases, would eliminate
the dilemmas of testing in a single
stroke. But such developments are
a long way off. Researchers at The
Rockefeller University and other insti
tutions are exploring the possibility
of using gene therapy-where healthy
genes are inserted into a sick person's
body-to treat certain genetic diseases
such as cystic fibrosis. But such experi
ments are still in very preliminary
stages, and treating a neurological

disease such as Huntington's would
pose many additional challenges as the
brain is a very delicate and complicat
ed target.
In the meantime, Wexler believes
that we need to face the widening
gap between our biological under
standing and society's ability to
encompass these new developments.
As chair of the joint National Insti
tutes of Health/Department of Energy
Ethical, Legal and Social Issues
Working Group, Wexler has struggled
with responding to some of the new
issues posed by genetic technology.
These challenges include ensur�
ing that those being tested understand
the risks of learning their genetic
status and providing enough counsel
ing to help them deal with the results.
Other challenges are protecting the
privacy of genetic information and
restricting its use so that it cannot be
used to deny employment, stigmatize
individuals for having "undesirable"
genes or prevent access to health care.
Wexler is especially worried about
the potential for abuse by insurance
companies. As it is, she points out,
she herself would normally be totally
uninsurable-not because she is sick,
but because of her genetic risk. As
genetic technology advances, insur
ance companies will have more and
more opportunities to deny or limit
coverage. "We have to be very explicit
and very unified in fighting this kind
of pernicious activity that distorts the
way health care is delivered in this
nation," she said.
Is Wexler sorry that she helped
open Pandora's box, playing a part in
ushering in this uncharted new age of
genetic information? While she admits
that for a time we may have the worst
of all possible worlds-limited or no
treatments, unrealistic expectations,
insurance repercussions-she is still
optimistic about the future. One day,
she hopes, genetic technology will lead
to a better world, one in which people
will no longer have to suffer the worst
of the fates written in their genes. [!]
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repeat. In a person
without Huntington's
disease, there are only
18 repeats ( left); the
DNA sequence of a per
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here
othing 1· n the known universe to com.
pare with t e human brain." So reads the
opening of the new book, The Hostage Brain,
written by Roe efeller Professor Bruce McEwen
k
rnalist Harold M. ScB.mecJ, Jr.
and veteran jeienc
In the 300 r so pages that follow, the authors proceei
_ J
to:.Show Just
how wondrous the human brain really is!
The new b00k,. ·published by The Rockefeller
University Pr. s, describes multiple influences on the
b&in such ,.as the surprising interactions that occur
between the brain and the immune system, with hor
mones'from the immune system affecting the brain,
and the brain innervating cells of the immune system
and bombarding them with neurotransmitters and
ormones. The book also describes the devastating
impact of neurological diseases such as Alzheimer's
and schizophrenia. It chronicles the impact of our
inner biological clocks on memory, alertness and
mood. It tracks the effect of aging on the brain.
And it explores the impact of a wide range of experi
ences such as learning, stress and interpersonal rela
ti <_;nships on the body's most complicated organ.
Many of McEwen's insights into the hostage brain
come from work in his own laboratory, which focuses
e effect of sex and stress hormones on the brain.
He first caught the bug for communicating these
insiglits when he gave the Alfred E. Mirsky Christmas
Lectures for High School Students in 1973. Three
years ago, McEwen teamed up with Schmeck, a veter
an science reporter who had recently retired from The
New York Times. Schmeck's distinguished career cov
ering scientific research provided him with a t{easure
trove of experience and anecdotes to make the science
come alive.:, ::fogetper, the two authors worked with
scientific"'tll�strator, Lyclia Kibiuk to produce a book
that aims to "reach out to every level of scientific
understan}ling, and to allow people who are not scien
tists to lear0. about the brain." McEwen hopes that

Above, Dr. Bruce McEwen, (right), and Harold M.

Schmeck, Jr., at the book launching party.

the book will be read by interested lay people, and
also used in high schools, adult evening schools and
certain medical school settings.
Each audience may take from the book different
levels of understanding, but McEwen hopes that every
reader will hear the book's fundamental message.
He says, "If you're a hostage, then there has to be a
ransom, or a way of breaking the bonds. And that
really has to do with using our intelligence to under
stand how the brain works. Many of our most vexing
problems-violence on our streets, stress in our lives,
anxiety, mental illness-are problems of behavior and
brain function that can be addressed more effectively
by understanding how the brain operates and how
it is capable of changing.
"The challenge to all of us is to use our brains\
to understand our brains and our behavior because
in the end, our !?rains are mainly hostage t� one
'
""'thing: ignorance?
Hardcover ($39,,JS,) and softcover (

:Z

.95) copies

o(The Hosfage Brain are available fwm 'Ehe Rockef,eller

University Press Order Service, 212.327.8'51<2 or
fax 212.327.7944.
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Blue colonies of a pneumococcal strain with a genetic defect in an exported
protein, left, compared to the white parental strain (magnification: 20).
Capitalizing on the 1944 discovery of Avery, Macleod and McCarty,
Rockefeller University investigator Robert Masure designed a genetic
strategy in 1994 to systematically map the surface of pneumococcus.

